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Summary
Background: The suitability of disease activity indices has been challenged, with
growing interest in objective measures of inflammation.
Aim: To undertake a systematic review of efficacy and safety outcomes in placebo‐
controlled randomised controlled trials (RCTs) of patients with Crohn's disease.
Methods: MEDLINE, EMBASE, CINAHL and Cochrane Library were searched until
November 2015, for RCTs of adult Crohn's disease patients treated with medical or
surgical therapies. Data on efficacy and safety outcomes, end‐point definitions, and
measurement instruments were extracted and stratified by publication date (pre‐
2009 and 2009 onwards).
Results: One hundred and eighty‐one RCTs (110 induction and 71 maintenance)
were identified, including 23 850 patients. About 92.3% reported clinical efficacy
endpoints. The Crohn's Disease Activity Index (CDAI) dominated, defining clinical
response or remission in 63.5% of trials (35 definitions of response or remission).
CDAI < 150 was the commonest endpoint, but reporting reduced between periods
(46.4%‐41.1%), whilst use of CDAI100 increased (16.8%‐30.4%). Fistula studies most
commonly reported fistula closure (9, 90.0%). Reporting of biomarker, endoscopy
and histology endpoints increased overall (33.3%‐40.6%, 14.4%‐30.4% and 3.2%‐
12.5%, respectively), but were heterogeneous and rarely reported in fistula trials.
Patient‐reported outcome measures were reported in 41.4% of trials and safety
endpoints in 35.4%. Many of the common adverse events relate to disease exacer-
bation or treatment failure.
Conclusion: Trial endpoints vary across studies, over time and are distinct in fistula
studies. Despite growth in reporting of objective measures of inflammation and in
patient‐reported outcome measures, there is a lack of standardisation. This confirms
the need for a core outcome set for comparative effectiveness research in Crohn's
disease.
Jamie Kirkham and Keith Bodger are joint senior authors.
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1 | INTRODUCTION
Defining the key outcomes of therapeutic interventions and the best
way to measure those outcomes is essential for clinical and regulatory
decision‐making. Due to the complexity of Crohn's disease and the
multitude of treatments, a number of different outcomes and out-
come measures have been reported in clinical trials including symp-
tom scores, composite disease activity indices and quality of life
questionnaires.1,2 Decision‐making also relies on the availability of
good information on the unintended effects (harms) from treatments.
Heterogeneity in reporting of outcomes or measurement instru-
ments within clinical trials may hinder the comparison of results
within systematic reviews and inhibit the meaningful interpretation
of individual studies.3 One way to mitigate this problem is the intro-
duction of an agreed minimum set of standardised outcomes, to be
measured and reported in all trials for a particular condition, referred
to as a core outcome set.4 There is no core outcome set for Crohn's
disease, although a model has been proposed for classifying out-
comes for all inflammatory bowel diseases using the World Health
Organisation International Classification of Functioning, Disability
and Health (ICF).5 Recently, the International Consortium for Health
Outcomes Measurement developed a “Standard Set” for inflamma-
tory bowel disease with recommendations for the pragmatic mea-
surement of outcomes in routine care to support benchmarking.6
Also recently published is a study protocol for the development of a
core outcome set for inflammatory bowel disease7 and a core out-
come set for fistulising Crohn's disease,8 indicating the importance
of this research area. Future trial design and core outcome set devel-
opment for Crohn's disease would benefit from a systematic synthe-
sis of outcome reporting across published clinical trials, incorporating
statistical testing and consideration of adverse events.
In this study, we systematically reviewed the literature to extract
data on the outcomes and measurement instruments used, and the
safety outcomes reported, in randomised clinical trials (RCTs) of
treatments for Crohn's disease. Our aims were to explore the extent
of heterogeneity among existing trials, to examine time trends in
reporting and to generate insights to support future trial design and
core outcome set development. Our results extend beyond the
recently published literature in this area by including a broader set
of interventions, offering statistical testing of time trends in outcome
reporting and bringing new evidence on harms reporting in Crohn's
disease.8,9
2 | METHODS
2.1 | Systematic search
We registered review protocols with the International Prospective
Register of Systematic Reviews (PROSPERO) database (CRD420
16027656 http://www.crd.york.ac.uk/PROSPERO) and the Core
Outcome Measures in Effectiveness Trials (COMET) database
(http://www.comet-initiative.org/studies/details/867).
We conducted a systematic electronic search of the Cochrane
Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE and
the Cumulative Index to Nursing and Allied Health Literature
(CINAHL) until November 2015, with no date limits. The disease
term “Crohn's disease” and the key word “outcome” were used. See
Tables S1 to S4 for detailed search criteria.
2.2 | Eligibility criteria and study selection
Randomised control trials of drug therapies (corticosteroids, 5‐ASAs,
immunosuppressants, biologics and antibiotics), surgery and nondrug
therapies (enteral nutrition, complementary and alternative medicine,
probiotics and prebiotics) were included, as were RCTs of treat-
ments for complications (strictures, fissures, abscesses and perfora-
tions). Eligible trials were conducted in adult patients (aged 18 or
over) with Crohn's disease. Studies of inflammatory bowel disease
populations were eligible provided outcomes were reported sepa-
rately for Crohn's disease. Studies had to be published as full text in
English.
Duplicates were removed after a complete list of RCTs was gen-
erated. Two reviewers (HC and JK) independently assessed the sam-
ple of 100 studies against eligibility criteria at the title and abstract
screening stages and resolved discrepancies by discussion. A random
sample of 100 was selected for review due to time constraints. The
sample was generated by assigning each article a number and using
a random number generator. There were no issues found when
screening the 100 articles and the primary researcher (HC) screened
the remaining papers independently. Full copies were obtained of all
potentially eligible studies and reassessed against eligibility criteria
by the primary researcher (HC). Reference was made to the second
reviewer (JK) where needed.
2.3 | Data collection
Data were extracted from the studies by the primary researcher. A
randomly generated sample of 10 studies were reviewed and data
extracted by the primary researcher and the secondary researcher
(JK) checked the extraction. No inaccuracies were found in the data
extraction of the sample of 10 papers and the primary researcher
extracted data from the remaining papers independently. Studies
were categorised as induction or maintenance with subcategories of
medical vs surgical induction and maintenance of medically induced
vs surgically induced remission. RCTs focusing solely on patients
with fistulising disease were flagged to identify differences in
reported outcomes. Efficacy and safety outcomes were recorded as
reported as primary or secondary outcomes, or not specified as
either. The efficacy outcomes were categorised in line with the
method used by Ma et al10 as clinical or composite‐clinical, endo-
scopic, histologic, biomarkers and patient‐reported outcomes (PROs).
Safety‐related outcomes were recorded as primary or secondary out-
comes.
Adverse event reporting was recorded in specific categories:
adverse events, serious adverse events, treatment‐related adverse
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events, treatment‐related serious adverse events, study withdrawal,
abnormal laboratory results and adverse events by preferred term
according to the Medical Dictionary for Regulatory Activities (Med-
DRA).11 Study withdrawals were categorised as due to adverse
events, serious adverse events, treatment‐related adverse events,
treatment‐related serious adverse events, treatment failure (insuffi-
cient therapeutic effect, exacerbation of Crohn's disease, develop-
ment of complications or need for additional therapy, surgery or
hospitalisation) or other reasons (protocol noncompliance, lost to fol-
low‐up, prohibited medicine use or withdrawal of consent).
A critique of the methodological quality of the studies was
unnecessary, as this project did not involve synthesis of outcome
data.
2.4 | Synthesis of results and analysis
A comprehensive record of efficacy and safety outcomes was gener-
ated and organised by outcome type. Our main analysis of efficacy
outcomes focused on those designated as primary or secondary end-
points. We adopted a similar approach for safety‐related outcomes
but also analysed all reported data for adverse events and study
withdrawals. Adverse event reporting was considered at two levels
of the MedDRA hierarchy: system organ classification (SOC) and
higher level group term, the latter of which is considered a clinically
relevant grouping of MedDRA preferred terms.11 Adverse events
were grouped by MedDRA higher level group terms and ranked in
the order of frequency of reporting. The top 10 ranked higher level
group term adverse events were compared by trial type and drug
class.
A secondary analysis considered the reporting of outcomes were
not specified as primary or secondary endpoints. To mirror the
increased focus on the importance of mucosal healing,12 the number
of studies that reported additional endoscopic or histologic out-
comes or the faecal calprotectin biomarker was assessed.
The proportion of studies reporting each type of outcome was
calculated, by trial type. The results were stratified by into pre‐2009
and 2009 onwards and the changes over time in reporting were
summarised in matrix form with outcome categories listed in rows
and frequency of outcome reporting plotted in greyscale on a time
axis.10 The statistical significance of any changes between time peri-
ods in outcome reporting was tested using the chi‐squared test (with
1 df, the critical value of chi is 3.84).
The review was reported in line with the Preferred Reporting
Items for Systematic Reviews and Meta‐Analyses (PRISMA) state-
ment and harms the checklist.13,14
3 | RESULTS
3.1 | Systematic search results
The search identified 9561 unique records (Figure 1) and included
181 RCTs (characteristics in Table S5). Induction of remission was
the focus of 110 studies: 104 (94.5%) through medical15–118 and six
(5.5%) through surgical approaches119–124(Table 1). Nine (of 110,
8.2%) induction studies solely treated patients with fistula with med-
ical36,64,79,86,91,110,113 or surgical119,120 therapies.
Maintenance of remission was the focus of 71 studies: 52
(73.2%) sought to maintain remission achieved through medical ther-
apies125–176 and 19 (26.8%) aimed to maintain surgically induced
remission.177–195 One study aimed to maintain medically induced
remission in fistula patients.146
In total, 23 850 patients were involved in the studies, with med-
ian follow‐up of 16 weeks (IQR: 8.0‐25.1) in induction studies and
52.0 weeks (IQR 48.0‐60.0) in maintenance studies. Over 30% of
studies were published after 2009 (56 of 181, 30.9%). Biologics
were the intervention of interest in 33.7% studies (61), either as
monotherapy or in combination.
Table 2 shows a summary of the primary and secondary out-
comes reported in Crohn's disease RCTs and highlights the wide
range of outcomes and outcome measures. The reporting of out-
comes not specified as primary or secondary endpoints was common
(158 studies, 87.3%) and was consistent across the two time
periods.
14 426 records identified 
through database searching
9561 records after duplicates 
removed
9561 record titles screened 4585 records excluded
4976 record abstracts 
screened
4755 records excluded
211 full-text articles assessed 
for eligibility
30 full-text articles excluded, 
with reasons
- Included under 18s (11)
- Not RCT (3) 
- Not full study (1)
- Not reporting outcomes 
for Crohn’s (3)
- Pooled or post-hoc 
analysis (6)
- Treatment for sequelae 
(2)
- Study protocol (2)
- Paper unavailable (2)
181 studies included in the 
review
F IGURE 1 Preferred reporting items for systematic review and
meta‐analyses (PRISMA) flow diagram
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3.2 | Efficacy outcomes
3.2.1 | Clinical or composite‐clinical
Clinical or composite‐clinical efficacy outcomes were reported as pri-
mary or secondary endpoints in 92.3% of trials, which was consis-
tent across the two time periods (Figure 2A).
Clinical response was reported by 70.0% (77) induction studies,
75 (of 104, 72.1%) medical and two (of six, 33.3%) surgical interven-
tions (Table S6). Clinical response was reported less frequently in
maintenance trials (31 of 71, 43.7%) but was more common in stud-
ies of maintenance of medically induced remission (26, 50%) than
surgically induced (5, 19.3%). Clinical response was an outcome in
80% (eight) of studies of patients with fistulae.
Clinical remission was reported in 65.5% (72) of induction studies
(all medical) and 19.7% (14) of maintenance studies. Clinical remis-
sion was not reported as a trial endpoint in surgical studies or stud-
ies of fistula patients.
Disease relapse or worsening was a primary or secondary out-
come in 12.7% of induction studies (13 medical and one surgical)
and 38 (73.1%) studies of maintenance of medically induced remis-
sion. Recurrence was reported in 14 (73.7%) maintenance studies of
surgery‐induced remission and one (16.7%) surgical induction study.
Fistula response and remission were commonly reported in fis-
tula studies (nine (90%) and six (60%), respectively). Overall, 14
(12.7%) induction studies and one (1.4%) maintenance study
reported fistula response and 10 (9.1%) induction and two (2.8%)
maintenance studies reported fistula remission.
Corticosteroid sparing and corticosteroid‐free remission were
reported in 11 (10.6%) and eight (7.7%) medical induction studies
and three (5.8%) and four (7.7%) maintenance studies of medically
induced remission respectively. All studies, with one exception,173
were published prior to 2009.
The Crohn's Disease Activity Index (CDAI) dominated as the pri-
mary measurement tool for primary and secondary outcomes with
77.9% (141) of studies reporting its use, which was common across
TABLE 1 Characteristics of randomised controlled trials in Crohn's disease
Induction (n = 110) Maintenance (n = 71) Total (n = 181)
Trial participants 13 153 10 697 23 850
Trial year publication
1979‐2008 78 (70.1) 47 (66.2) 125 (69.1)
2009‐2015 32 (29.1) 24 (33.8) 56 (30.9)
Country of lead author
UK and Europe 61 (55.5) 40 (56.3) 101 (55.8)
USA and Canada 39 (35.5) 24 (33.8) 63 (34.8)
Rest of the world 10 (9.1) 7 (9.9) 17 (9.4)
Subgroup
Medically induced 104 (94.5) 52 (73.2) 156 (86.2)
Fistula 7 (6.4) 1 (1.4)
Surgically induced 6 (5.5) 19 (26.8) 25 (13.8)
Fistula 2 (1.8) 0
Intervention of interest
5‐ASAs 3 (2.7) 8 (11.3) 11 (6.1)
Antibiotics 8 (7.3) 3 (4.2) 11 (6.1)
Biologics 40 (36.4) 15 (21.1) 55 (30.4)
Corticosteroids 9 (8.2) 9 (12.7) 18 (9.9)
Immunosuppressants 7 (6.4) 7 (9.9) 14 (7.7)
Surgery 6 (5.5) 0 6 (3.3)
Dietary 16 (14.5) 5 (7.0) 21 (11.6)
CAM, prebiotics/probiotics 8 (7.3) 15 (21.1) 23 (12.7)
Combination interventions 6 (5.5) 8 (11.3) 14 (7.7)
Other 7 (6.4) 1 (1.4) 8 (4.4)
Comparator intervention
Placebo 66 (60.0) 45 (63.4%) 111 (61.3)
Active 44 (40.0) 26 (36.6) 70 (38.7)
Follow‐up (wk) 16 (8.0‐25.1) 52.0 (48.0‐60.0) 25.1 (12.0‐52.0)
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TABLE 2 Primary and secondary outcomes and measurement tools reported in randomised controlled trials in Crohn's disease
Outcome category Primary or secondary outcomes Measurement tools
Clinical or composite‐
clinical
Clinical response (110)
Clinical remission (85)
Disease relapse or worsening (51)
Fistula remission (10)/response (17)
Corticosteroid‐sparing (14)
Corticosteroid‐free remission (12)/response
Recurrence (2)
Sustained remission (11)/response (3)
Combined clinical and endoscopic remission (1)/
recurrence (3)
Post‐operative recovery (2)
Sustained corticosteroid‐free remission (2)
Sustained fistula remission (2)
Treatment compliance (2)
Complete response (1)
Crohn's Disease Activity Index (141)
Harvey Bradshaw Index (12)
Physician Global Assessment (10)
Perianal Disease Activity Index (6)
Van Hees Activity Index (5)
Severity and Activity Index (2)
European Co‐operative Crohn's Disease Study based ranking
system (1)
Clinical recurrence grading scale (1)
Dutch Index (1)
International Organisation of Inflammatory Bowel Disease (IOIBD)
score (1)
Partial Harvey Bradshaw Index (1)
Present Score (1)
Endoscopy Endoscopic recurrence (21)
Endoscopic response (16)
Endoscopic mucosal healing (4)
Endoscopic remission (1)
Rutgeerts endoscopic score (20)
Crohn's Disease Endoscopic Index of Severity (12)
Simple Endoscopic Score for Severity (4)
D'Haen's endoscopic categories (1)
Marteau endoscopic score (1)
Histology Histologic recurrence (4)
Tissue cytokine, leucocyte, receptor or gene
expression (4)
Histologic response (3)
Histologic remission (1)
Average Histology Score (1)
D'Haens‐Geboes score (4)
Dieleman histological score (1)
Histological Activity Score (1)
Regueiro histology score (1)
Biomarkers Serum C‐reactive protein (34)
Serum erythrocyte sedimentation rate (16)
Antidrug antibodies (10)
Drug concentration and pharmacokinetics (8)
Serum cortisol level (8)
Serum full blood count and subsets (7)
Serum protein concentrations (6)
Intestinal permeability (4)
Serum albumin (3)
Autoantibodies (2)
Faecal calprotectin (2)
Serum lymphocyte count and subset expression (2)
Serum cytokine or immunoglobulin levels (1)
Economic outcomes Cost of treatment (3)
Utility (1)
Quality‐adjusted life years (1)
Patient‐reported
outcomes
Quality of life (70)
Pain (5)
Defaecation functions (5)
Bowel symptoms (2)
Treatment compliance (2)
Treatment acceptability (1)
IBDQ (55)
SF‐36 (10)
Patient Global Assessment (4)
Visual analogue scale (4)
Gastrointestinal Quality of Life Index (2)
Hamilton Depression Scale (2)
Short IBDQ (2)
16 PROM instruments were used once and are recorded in
Table S9
Safety‐related outcomes Adverse events (60)
Abnormal laboratory or ECG parameters (25)
Complications of surgery (2)
Death (3)
Medical dictionary for regulatory activitiesa
Coding symbols for a thesaurus of adverse reactions termsa
WHO toxicity grading criteriaa
AEs, adverse events; ECG, electrocardiogram; IBD, inflammatory bowel disease; IBDQ, inflammatory bowel disease questionnaire; IBS, irritable bowel
syndrome; SF‐12, Short‐Form 12; SF‐36, Short‐Form 36; WHO, World Health Organisation.
aNumber of reports not available.
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both induction (86, 78.2%) and maintenance (55, 77.5%) studies. The
use of CDAI to measure primary and secondary outcomes reduced
from 79.2% of studies pre‐2009, to 75.0% from 2009 onwards,
although the chi‐squared value of 0.4 demonstrates that this was
not a statistically significant result at the 95% confidence level. Out-
come definitions using the CDAI were heterogeneous with 35 differ-
ent definitions of response or remission reported (Table S6). CDAI
100 was the reported response measurement in 38 (21.0%) studies,
only one before 2000.21 CDAI 70 was also reported in 38 (21.0%)
studies, all but three after 2001. The remission benchmark CDAI
<150, was the commonest (81, 44.8%), but reporting reduced
between the two time periods (46.4%‐41.1%). Conversely, the
reporting of CDAI 70 and CDAI 100 increased between the periods
(20.8%‐21.4% and 16.8%‐30.4% respectively). The increase in CDAI
100 reporting was statistically significant at the 95% confidence
level (chi‐squared value of 4.29). Fistula studies most commonly
reported the change in CDAI score (5, 50%).
Other tools used less frequently to measure clinical
response or remission include the Harvey Bradshaw
Index,19,28,48,49,87,100,118,131,157,196 Physician Global Assess-
ments19,20,25,48,99,111,180 and the Van Hees Activity Index19,41,66,87,131
(Table 2). The Perianal disease Activity Index was used in four (40%)
studies of fistula patients and in one nonfistula study. 36,64,91,94,120
There were 30 definitions of disease worsening or relapse, or
recurrence using the CDAI, many of which required the CDAI to
exceed a benchmark level such as 150, 200 or 250, with or without
an increase from baseline score (Table S6). The need for additional
therapy and/or surgery were commonly used to define worsening or
relapse of disease.
Studies of penetrating disease most commonly used physician
assessments of draining fistulas (50% [9, 90.0%] or 100% [6, 60%]
reduction from baseline) as trial endpoints. Two (20.0%) studies of
fistula patients used imaging techniques, MRI and diagnostic ultra-
sound, to assess response, one in each time period.64,120
3.2.2 | Endoscopy
The reporting of endoscopic outcomes doubled between the two
time periods, from 14.4% to 30.4% of studies (Figure 2A). This
increase was statistically significant with a chi‐squared value of 6.31
(95% confidence level). Endoscopic outcomes were reported in 31%
(22) of maintenance trials, with reporting more likely in studies of
Clinical or composite-clinical
outcomes
Endoscopic outcomes
Histologic outcomes
Biomarker and serologic 
outcomes
Economic outcome
Patient reported outcome
Safety-related outcomes
1979-2008 2009-2015
32.8%
46.4%
39.2%
35.7%
32.0%
12.5%
3.2%
14.4%
92.9%
10
0.0
%
90
.0%
80
.0%
70
.0%
60
.0%
50
.0%
40
.0%
30
.0%
20
.0%
10
.0%
0.0
%
92.0%
30.4%
3.6%
0.8%
41.1%
Outcome type
Endoscopic outcomes
Histologic outcomes
Biomarker outcomes
Patient-reported outcomes
Economic outcomes
Safety-related outcomes (Pri or Sec)
Adverse event reporting   
Clinical or composite-clinical outcomes
19
79
19
89
19
99
20
09
20
15
1 paper
2 papers
3 papers
4 papers
5-7 papers
8-10 papers
>10 papers
(A)
(B)
F IGURE 2 A, Proportion of Crohn's disease randomised controlled trials reporting key primary and secondary efficacy and safety outcomes,
stratified by date of publication. B, Outcome reporting matrix for randomised controlled trials for Crohn's disease
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surgically (19, 100.0%) than medically (3, 5.8%) induced remission.
Endoscopic outcomes were infrequently reported in induction trials
(13, 11.8%) and in trials in penetrating disease (1, 10.0%).120 Report-
ing of endoscopic outcomes is a more recent phenomenon in induc-
tion trials, with their first use in a study reported in 2000, as
compared with 1984 in maintenance trials.
Endoscopic recurrence was the most frequent endpoint, espe-
cially in maintenance trials (19, 26.8%). Only two induction stud-
ies122,123 reported endoscopic recurrence, both of which involved
surgery. Endoscopic response was more frequently reported in
induction trials (10, 9.1%) than in maintenance trials (6, 8.5%). Endo-
scopic mucosal healing was reported in two (1.8%) induction88,111
and two (2.8%) maintenance162,189 studies and endoscopic remission
in one (0.9%) induction study.102
Endoscopic recurrence was commonly defined with the Rutgeerts
endoscopic score>=2 (14, 7.7%),122,179–181,183,185,187,188,190–,193,195
although many benchmarks were used (Table S7). Endoscopic out-
comes in induction (and fistula) trials report changes in the Crohn's
Disease Endoscopic Index of Severity (CDEIS) score (9,
5.0%)40,69,73,76,93,98,102,112,120 or changes in the Simple Endoscopic
Score for Crohn's Disease (SES‐CD) (4, 2.2%)88,98,111,120 in place of
the Rutgeerts score. The D'Haens162 and Marteau191 endoscopic
scores were used infrequently.
Endoscopic outcomes were reported in 13.3% of studies (24) as
additional outcomes and reporting increased pre‐2009 to 2009
onwards (12.0%‐16.1%), with the reporting growth exclusively in
maintenance studies. This result was not statistically significant at the
95% confidence level (based on a chi‐squared test value of 1.58).
3.2.3 | Histology
Histology‐based outcomes have shown a statistically significant
increase between the two periods (chi‐squared test statistic of 5.86)
(Figure 2A), but remain uncommonly used (11, 6.1%) and are unused
in studies of fistula patients. Three (medical) induction studies
(1.7%)62,102,112 reported histologic response, one maintenance study
(1.9%) of medically induced remission162 reported histologic remis-
sion and four maintenance studies (21.1%) of surgically induced
remission179,182,188,193 reported histologic recurrence. Three induc-
tion studies (1.7%)40,62,97 and one maintenance study (1.4%)194
reported outcomes related to cytokine expression in mucosal tissues.
A number of histology scores are used including
D'Haens,62,112,182,188 Dieleman102 and Reguiero193 (Table S8). The
reporting of histologic outcomes as additional outcomes increased
between the time periods from 3.2% of studies to 7.1%, but this is
not statistically significant at the 95% confidence level.
3.2.4 | Biomarkers
Biomarker outcomes were reported in 39 (35.5%) induction studies,
38 (36.5%) medical interventions and one (16.7%) surgical120 and 21
(29.6%) maintenance trials. Reporting has increased over time with
35.7% of trials since 2009 reporting a primary or secondary
biomarker outcome (Figure 2A). However, this increase was not sta-
tistically significant. Only one (10.0%) study of penetrating disease
reported a biomarker outcome.120 Serum C‐reactive protein was the
most reported biomarker (34, 18.8%), followed by serum erythrocyte
sedimentation (16, 8.8%). Faecal calprotectin was reported as an out-
come in only two studies (1.1%),66,101 one in each time period. The
biomarker was an additional outcome in three (1.7%) further tri-
als,114–116 all reported between 2014 and 2015.
3.2.5 | Patient‐reported outcomes
Patient‐reported outcomes (PROs) were reported in 47 (42.7%)
induction studies, 45 (43.3%) medical induction studies and two
(33.3%) surgical induction studies.120,121 Reports of PROs were simi-
lar in studies of fistula patients (4, 40.0%). Primary or secondary
PROs were reported in 28 (39.4%) maintenance studies, 24 (46.1%)
of medically induced remission (46.1%), and four (21.1%) of surgically
induced remission.179,189,190,194 The use of PROs has increased over
time, although not with statistical significance at the 95% confidence
level, with almost half of RCTs reporting a primary or secondary
PRO since 2009 (Figure 2A). Quality of life was the most common
outcome, reported in 40.3% (73) of studies (Table S9). The Inflamma-
tory Bowel Disease Questionnaire (IBD‐Q) was frequently used to
record quality of life (59, 32.6%), and typically outcomes were speci-
fied as the final score or changes in the score (from baseline, mean
or median). The use of IBD‐Q to measure PROs increased from
30.4% to 37.5% between 1979‐2008 and 2009‐2015. The growth in
use was in maintenance studies (25.5%‐50.0%), whilst its use in
induction studies reduced (33.3%‐28.1%). Whilst the overall change
in IBDQ use and the decline in induction trials were not statistically
significant at the 95% level, the increase in IBDQ studies in mainte-
nance trials was significant (chi‐squared test value of 0.89, 0.28 and
4.25 respectively). Reporting of IBD‐Q in studies of fistula patients
was in line with the overall average (3, 30.0%).
Other tools for measuring quality of life included the Short‐Form
3640,50,106,120,121,153,160,161,169,173 and its components,50,121,169
Patient Global Assessments,48,91,179 the Gastrointestinal Quality of
Life Index,111,121 the Hamilton Depression Scale81,95 and the Short
IBDQ.46,120 Patient diaries were used to measure outcomes related
to bowel symptoms,38 defaecation functions19,46,86,96 and pain19,46,86
(Table 2), with reports comparatively high (2,20%) in fistula patient
studies.86,120
3.3 | Safety outcomes
Safety outcomes were specified as primary or secondary outcomes in
42 (38.2%) induction studies, 38 (36.5%) medical and four (66.7%) sur-
gical.119–122 Twenty‐two maintenance studies (31.0%) also reported
primary or secondary safety outcomes. Safety outcome reporting
increased from 32.8% of studies pre‐2009 to 41.1% between 2009
and 2015, although the increase was not statistically significant.
Safety‐related primary and secondary outcomes were reported in
three (30.0%) studies in fistula patients, all since 2010.119,120,189
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Adverse events were the most common primary and secondary
outcomes, reported in 39 (35.5%) induction and 22 (31%) mainte-
nance studies. The reporting of adverse events as a primary or sec-
ondary endpoint was most frequently the totality of adverse events
but some studies looked for specific treatment‐related adverse
events or reported the stopping of treatment due to adverse
events.
3.3.1 | Adverse events
Reporting of any adverse events occurred in 88 (80%) induction
studies and 61 (85.9%) maintenance studies. All of the fistula studies
reported adverse events. Reporting of adverse events increased
slightly between the two periods from 80.0% to 87.5%. Serious
adverse events were reported in 60 (54.5%) induction and 31
(43.7%) maintenance studies, and were higher in fistula patient trials
(6, 60.0%). The reporting of serious adverse events in studies
increased from 46.4% before 2009 to 58.9% from 2009 to 2015.
Treatment‐related adverse events (including serious events), were
reported in 69 (62.7%) induction and 44 (62%) maintenance studies.
Six (60.0%) fistula studies reported treatment‐related adverse events.
The reporting of treatment‐related adverse events (including serious)
grew from 56.8% to 66.1% between the time periods respectively.
None of the changes in reporting of adverse events was statistically
significant at the 95% confidence level.
Gastrointestinal adverse events, including the exacerbation of
Crohn's disease and gastrointestinal signs and symptoms, were the
most commonly reported adverse events by MedDRA SOC, reported
in 85 (77.3%) induction trials and 57 (80.3%) maintenance studies.
The 10 most commonly reported adverse events by higher level
group term (HLGT, a clinically relevant grouping) are shown in
Table 3. Gastrointestinal signs and symptoms, including nausea, vom-
iting and pain, were reported as adverse events in 65.2% (118) of
studies. Two other higher level group terms within the gastrointesti-
nal conditions were in the 10 most reported: gastrointestinal inflam-
matory conditions (71, 39.2%), which includes Crohn's disease
exacerbation as an adverse event, and gastrointestinal motility and
defaecation conditions (63, 34.8%). Joint disorders, another higher
level group term possibly related to Crohn's disease and the failure
of treatment, were reported in 32.6% (59) studies.
3.3.2 | Adverse events by intervention group
Five of the 10 most commonly reported adverse event groups for all
therapies were also in the top 10 across all intervention groups
(Table 3). Gastrointestinal signs and symptoms, infections (including
anal abscess, post‐operative wound infection, urinary tract infection,
upper respiratory tract infection and pneumonia) and headaches, the
three most common adverse event groups for all trials, were ranked
in the top four most reported for all trial subtypes. Gastrointestinal
inflammatory conditions (Crohn's disease exacerbation) and gastroin-
testinal motility and defaecation were also commonly reported
across all trial subtypes.
General system disorders, such as fatigue, pain, flushing, oedema,
chills, influenza like illness, were commonly reported only in trials of
medical induction or maintenance of medically induced remission
interventions. Neurological disorders, such as dizziness, dysgeusia,
paraesthesia, syncope and somnolence, and epidermal and dermal
conditions, such as rash, pruritis, skin disorder, erythema and eczema,
were in the list of ten most recorded adverse event groups across all
trials, but were only commonly reported in medical induction trials.
Body temperature, specifically pyrexia, was one of the 10 most
commonly reported adverse events in induction trials, but not main-
tenance. Procedural related injuries and complications, such as post‐
operative ileus, post‐procedural haemorrhage, post‐procedural com-
plication, infusion‐related reaction, anastomic leak and the need for
therapeutic procedures and support care, such as surgery, hospitali-
sation and fistula repair, were only commonly reported in surgical
induction and post‐operative maintenance trials.
3.3.3 | Adverse events by drug class
Gastrointestinal signs and symptoms, and infections were the only
two adverse event groups that were consistently ranked in the 10
most commonly reported across all drug classes (including CAM,
dietary and prebiotic/probiotic interventions) (Table 4). General sys-
tem disorders, such as fatigue, asthenia, pain and chills, gastrointesti-
nal inflammatory conditions (Crohn's disease exacerbation) and joint
disorders were in the 10 most common adverse events across all but
one drug class (corticosteroids, immunosuppressives and CAM
respectively).
Headaches were one of the 10 most common adverse event
groups in all drug classes except antibiotics and prebiotics. Gastroin-
testinal motility and defaecation conditions were one of the 10 most
commonly occurring adverse events across all drug groups, with the
exception of corticosteroids and immunosuppressives.
Differences between drug classes and from the overall average
were found. Skin appendage conditions were the fourth most com-
mon adverse events for 5‐aminosalycylic acid (5‐ASA) therapies,
specifically alopecia and night sweats. Skin appendage conditions
were the second most common adverse event grouping for corticos-
teroids, including acne, alopecia, hypertrichosis, hyperhidrosis and
abnormal hair growth. Adrenal gland disorders, specifically Cushin-
goid, Cushing's syndrome, adrenal disorder and adrenal suppression,
were the most common adverse events recorded by group and lipid
metabolism disorders (lipohypertrophy) and were the fifth most com-
mon for corticosteroids. Neither adverse event group was commonly
reported in any other drug class.
For the antibiotic drug class, bacterial infectious disorders (specif-
ically clostridium difficile infection and furuncle) were the third most
common adverse events, and were not common for any other drug
class. Therapeutic procedures and supportive care, specifically sur-
gery, hospitalisation and abscess drainage, were the third most com-
monly reported adverse event group for antibiotics, as it was for
dietary treatments. Procedural related injuries and complications
(procedural complication and feeding tube complication),
8 | CATT ET AL.
gastrointestinal haemorrhages and gastrointestinal stenosis and
obstruction, were also ranked the third most common adverse event
groups for dietary treatments.
Commonly occurring adverse events, unique to immunosuppres-
sive (ranked fifth and above) were white blood cell disorders, specifi-
cally leukopenia and lymphopenia. Body temperature conditions
(pyrexia), musculoskeletal and connective tissue disorders (back pain,
fistula and anal fistula) and hepatobiliary investigations (including ala-
nine aminotransferase increased and liver function test abnormal)
were also in the top five most commonly reported adverse events
for immunosuppressives, although each was also commonly reported
in other drug classes.
Injuries were the fourth most commonly reported adverse event
groups for CAM and prebiotic or probiotic trials. However, with
underlying terms including stab wound and road traffic accident,
these are likely to be unrelated to the interventions.
Surgical interventions offer a different pattern of adverse events,
as shown in Table 3. Infections are most commonly reported, fol-
lowed by procedural related injuries and complications (including
post‐operative ileus, post‐procedural haemorrhage, post‐procedural
complication, infusion‐related reaction and anastomic leak), and ther-
apeutic procedures and supportive care (Surgery, hospitalisation,
adhesiolysis and abscess drainage). Gastrointestinal signs and symp-
toms, which are generally very commonly reported in drug classes
TABLE 3 Ten most commonly reported MedDRA higher‐level group terms in randomised controlled trials in Crohn's disease, by intervention
type
SOC HLGT
All
therapies
rank
Medical
induction
rank
Surgical
induction
rank
Maintenance ‐
medical rank
Maintenance ‐
surgical rank
Fistula
rank
Gastrointestinal disorders Gastrointestinal signs and
symptoms
1 1 4= 1 1 2=
Infections and infestations Infections—pathogen
unspecified
2 3 1 2 2= 1
Nervous system disorders Headaches 3 2 4= 3 4= 4=
General disorders and
administration conditions
General system disorders
NEC
4 4 5 4=
Gastrointestinal disorders Gastrointestinal inflammatory
conditions
5 5 4= 6= 8= 2=
Gastrointestinal disorders Gastrointestinal motility and
defaecation conditions
6 7= 4= 4 2= 7=
Musculoskeletal and
connective tissue
disorders
Joint disorders 7 6 6= 4=
General disorders and
administration conditions
Fatal outcomes 8 4=a 8
Nervous system disorders Neurological disorders NEC 9= 10 7=
Skin and subcutaneous
tissue disorders
Epidermal and dermal
conditions
9= 7=
Skin and subcutaneous
tissue disorders
Skin appendage conditions 4=a 9 4=b
General disorders and
administration conditions
Body temperature conditions 7= 4=a
Injury, poisoning and
procedural complications
Procedural related injuries
and complications NEC
2= 7=
Surgical and medical
procedures
Therapeutic procedures and
supportive care NEC
2= 8=
Gastrointestinal disorders Gastrointestinal stenosis and
obstruction
4=a 8= 7=
Infections and infestations Viral infectious disorders 4=a 7=
Musculoskeletal and
connective tissue
disorders
Musculoskeletal and
connective tissue disorders
NEC
4=a 10 4=
aHigher level group terms (HLGTs) reported in equal numbers only in surgical trials: anal and rectal conditions NEC, gastrointestinal haemorrhages NEC,
gastrointestinal vascular conditions; protein and chemistry analyses NEC; appetite and general nutritional disorders; miscellaneous and site unspecified
neoplasms malignant and unspecified), gastrointestinal therapeutic procedures; and embolism and thrombosis.
bHLGT reported in equal numbers but only in post‐operative maintenance trials: hepatobiliary investigations.
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TABLE 4 Ten most commonly reported MedDRA higher level group terms in randomised controlled trials in Crohn's disease, by drug class
SOC HLGT
All
rank
5‐ASAs
rank
Antibiotics
rank
Biologics
rank
Corticosteroids
rank
Immunosuppressive
rank
Dietary
rank
CAM
rank
Prebiotics/
probiotics
rank
Gastrointestinal
disorders
Gastrointestinal
signs and
symptoms
1 1 1 1= 3 1= 2 2= 1
Infections and
infestations
Infections—
pathogen
unspecified
2 10= 2 3 9=a 3 3=a 4= 3
Nervous system
disorders
Headaches 3 4= 1= 5=a 1= 9=a 4=
General
disorders and
administration
conditions
General system
disorders NEC
4 3 10= 5 4= 3=a 1 8=
Gastrointestinal
disorders
Gastrointestinal
inflammatory
conditions
5 10= 6= 4 4 9=a 4= 4=
Gastrointestinal
disorders
Gastrointestinal
motility and
defaecation
conditions
6 2 6= 10=a 1 2= 2
Musculoskeletal
and connective
tissue
disorders
Joint disorders 7 8= 6= 7=a 7=a 5=a 9=a 8=a
General
disorders and
administration
conditions
Fatal outcomes 8 10= 6 9=a 4=
Nervous system
disorders
Neurological
disorders NEC
9= 4= 3=a 5=a 9=a 4=
Skin and
subcutaneous
tissue
disorders
Epidermal and
dermal
conditions
9= 4= 10= 10=a 5=a
General
disorders and
administration
conditions
Body
temperature
conditions
10= 7=a 5=a
Endocrine
disorders
Adrenal gland
disorders
1
Injury, poisoning
and procedural
complications
Injuries NEC 4= 4=
Surgical and
medical
procedures
Therapeutic
procedures and
supportive care
NEC
10= 3=a 3=a
Gastrointestinal
disorders
Gastrointestinal
stenosis and
obstruction
8= 3=a 8=a
Musculoskeletal
and connective
tissue
disorders
Musculoskeletal
and connective
tissue
disorders NEC
5= 9=a 4=
(Continues)
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(ranked first to third most common), are the fourth most common
adverse event for surgical interventions, along with headaches and a
number of other adverse event groups (Table 3).
3.3.4 | Study withdrawals
Withdrawals were most frequently reported due to adverse events
(102, 56.4%) and least frequently for serious adverse events (7,
3.9%). Withdrawals due to treatment failure were reported in
41.4% of studies, and in 45.9% of studies for reasons related to
noncompliance and loss to follow‐up, the reporting of both
reduced between periods (45.6%‐32.1% and 52.0%‐32.1% respec-
tively). Withdrawals due to treatment‐related adverse events (in-
cluding serious) were reported by 13.8% (25) studies, but the
proportion fell from 15.2% to 10.7% between the two time peri-
ods. The reduction in the reporting of study withdrawals was com-
mon across all categories except serious adverse events, which
rose slightly from 3.2% to 5.4% of studies. It was not possible to
test the increase in serious adverse events for statistical signifi-
cance, as the requirement for 80% of numbers to be over five
was not met. No changes in reporting reached statistical signifi-
cance, except the reduction in withdrawals due to other reasons,
which was significant at the 95% confidence level (chi‐squared test
value of 6.14).
4 | DISCUSSION
We conducted a comprehensive and independent systematic review
of the outcomes and outcome measures reported in RCTs of inter-
ventions for Crohn's disease, summarising data from 181 RCTs. A
key strength of our review was the focus on synthesising data on
safety outcomes and adverse events, which goes beyond anything
reported previously in the literature. Furthermore, we have not only
described temporal trends in outcome reporting but have tested the
statistical significance of these findings. Our results demonstrate that
trialists have adopted a wide and variable approach to outcomes
measurement and highlight commonalities and differences in the
reporting of adverse events between a variety of interventions to
induce or maintain remission in Crohn's disease. These results pro-
vide insights to guide future trial design and support core outcome
set development.
The CDAI was developed over 40 years ago as a composite mea-
sure incorporating symptoms, signs and simple laboratory parame-
ters.197 It was the dominant measurement instrument used in the
published trials, but with substantial variation including 35 defini-
tions of response or remission. Whilst this observation highlights a
need for greater standardisation of endpoints, the CDAI per se is
increasingly regarded as suboptimal as an endpoint for comparative
effectiveness research and regulatory approval. The index does not
TABLE 4 (Continued)
SOC HLGT
All
rank
5‐ASAs
rank
Antibiotics
rank
Biologics
rank
Corticosteroids
rank
Immunosuppressive
rank
Dietary
rank
CAM
rank
Prebiotics/
probiotics
rank
Skin and
subcutaneous
tissue
disorders
Skin appendage
conditions
4= 2 8=a
Surgical and
medical
procedures
Gastrointestinal
therapeutic
procedures
9=a 4= 4=
Infections and
infestations
Fungal
infectious
disorders
6= 8=a
Investigations Hepatobiliary
investigations
10= 4= 8=a
Infections and
infestations
Viral infectious
disorders
10=a 9=a
Musculoskeletal
and connective
tissue
disorders
Muscle
disorders
10= 10=
aHigher level group terms (HLGTs) reported in equal numbers only in one drug class: 5‐ASAs trials: 10 = renal disorders (excl nephropathies); exocrine
pancreas conditions. Antibiotic trials: 3 = bacterial infectious disorders. Biologics trials: 7 = toxicology and therapeutic drug monitoring; 10 = administra-
tion site reactions. Corticosteroids trials: 5 = lipid metabolism disorders. 7 = endocrine disorders of gonadal function. 9 = coagulopathies and bleeding
diatheses (excl. thrombocytopenic); cornification and dystrophic skin disorders. Immunosuppressives trials: 5 = white blood cell disorders. Dietary trials:
3 = procedural related injuries and complications; gastrointestinal haemorrhages NEC. 9 = anaemias nonhaemolytic and marrow depression; lipid analy-
ses; pregnancy, labour, delivery and postpartum conditions; suicidal and self‐injurious behaviours NEC; appetite and general nutritional disorders. Prebi-
otic/probiotic trials: 8 = cutaneous neoplasms benign; central nervous system vascular disorders; depressed mood disorders and disturbances; bronchial
disorders (excl. neoplasms); peritoneal and retroperitoneal conditions; miscellaneous and site unspecified neoplasms malignant and unspecified.
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correlate closely with objective signs of inflammation or with muco-
sal healing at endoscopy.198,199 The time trends we observed in clini-
cal trials outcomes reporting, specifically the statistically significant
increase in endoscopy and histology outcomes reporting, illustrate
how the emphasis is shifting towards inclusion of discrete, objective
measures of the inflammatory process. Whilst the use of CDAI over-
all has shown nonstatistically significant growth, the use of CDAI
100 has significantly increased, highlighting a continued interest in
this measure of response. This confirms that the CDAI 100, which is
a 100 point reduction in CDAI score, is increasingly preferred to the
CDAI 70 (70 point reduction in response), as a measure of
response.200
C‐reactive protein is a routinely employed biomarker in clinical
practice and was frequently reported among clinical trial outcomes,
albeit rarely as a primary outcome (five studies). However, C‐reactive
protein lacks sensitivity for active intestinal inflammation in Crohn's
disease,201 and this limits its value as a primary endpoint. There
remains active exploration of alternative serum markers of disease
activity202 but our review suggests no strong candidate has
emerged.
Stool biomarkers offer potential to reliably measure gut‐related
inflammation and in recent years faecal calprotectin has become
available in routine IBD practice.203 Uncertainty remains as to its
performance properties particularly for measuring small bowel, rather
than colonic, disease activity204 and research continues to explore
other stool assays to measure the inflammatory process.205 Faecal
calprotectin was reported as an endpoint in only two trials included
in this review.66,101
We found a statistically significant increase in the report of
endoscopy and histology‐based outcome measures over time, albeit
they remained at a low level and without emergence of a standard-
ised approach. This heterogeneity likely reflects the current subopti-
mal psychometric properties of individual measurement tools, both
for endoscopic and histologic scoring systems.206,207 In addition to
the cost and invasiveness of ileocolonoscopy, endoscopy is not able
to fully characterise small bowel disease or quantify the overall
extent of intestinal inflammation in Crohn's disease. There is a grow-
ing body of research on the potential use of quantitative imaging
such as CT and MRI,208 but only one trial included in this review
included radiological outcomes.120
Patient‐reported outcome measures (PROMs) were reported as
endpoints in almost half of studies reported since 2009, although
commonly as a secondary outcome (60, 33.1%) rather than a primary
outcome (10, 5.5%). Questionnaires administered in clinical trials ran-
ged from ‘generic” (eg EQ‐5D) and “disease specific” (eg IBD‐Q)
health‐related quality of life instruments to tools focusing on individ-
ual domains (eg Fatigue Impact Score). The IBD‐Q was the most fre-
quently reported PROM in the trials (85% of studies reporting
PROMs) and there was a statistically significant increase in its use
for measuring outcomes in maintenance studies over the time of the
review (from 25.5% to 50.0%). However, it was not developed
according to the latest FDA recommendations for product labelling
claims.209 New disease‐specific PROMs tools are under development
to meet the stringent guidelines and enable PROMs to support
future regulatory approvals of licencing for Crohn's disease.
Our review covered data for safety outcomes in clinical trials and
we found substantial heterogeneity in reporting, which highlights the
challenges in categorising adverse events for a complex, chronic con-
dition with a variable disease course and multisystem manifestations.
Lack of treatment efficacy in Crohn's disease may manifest with a
diversity of symptoms, which are difficult to distinguish from gen-
uine treatment side effects. Many of the most commonly reported
adverse events, such as gastrointestinal signs and symptoms and
gastrointestinal inflammatory conditions may reflect disease course.
Nevertheless, these data demonstrate differences in the adverse
event profile of different intervention groups and should support
renewed attempts to define disease‐ and intervention‐specific
adverse events and to standardise safety outcomes as discrete end-
points. This is an important consideration for future core outcome
set developers.
Our results highlight how the reporting of outcomes in trials in
fistula patients align with overall reporting. The use of PROMS and
safety‐related endpoints is common across all trials, regardless of dis-
ease type. Clinical response was less commonly measured by CDAI,
and more frequently measured by fistula closure and the PDAI.
These three outcome measures were the most commonly used in
fistula trials identified by this review, which supports the findings of
a recently developed core outcome set for fistulising disease.8 Bio-
marker, histology and endoscopy outcomes were rarely used in fis-
tula trials and are not included in the core outcome set either,
contrary to the general shift in outcomes reporting in Crohn's dis-
ease trials. However, patient reports (eg incontinence and drainage)
were more common endpoints in trials of fistula patients than in
nonfistula trials, and their importance is borne out in the core out-
come sets, which lists several PROMs to be reported in future trials.
Our review independently supports the key findings of a recently
published systematic review of outcomes in Crohn's disease.9 We
confirm heterogeneity in definitions of response and remission and
the need for a core outcome set to standardise endpoint definitions.
Both studies identified the use of CDAI as the most popular out-
come measurement tool overall and of IBD‐Q as the most commonly
used PROM. Our results confirm statistically significant increases in
the use of CDAI100 across all trials and of IBD‐Q reporting in main-
tenance trials across the time periods of the review. Similarly, the
CDEIS and the SES‐CD are highlighted as endoscopic tools most
used in induction trials and Rutgeerts in post‐surgical trials. Both
reviews confirmed the common use of C‐reactive protein and
increasing use of biomarkers.
However, our study had less restrictive inclusion criteria, leading
to inclusion of a larger number of RCTs (181 vs 116) with a wider
variety of interventions included. Our research included dietary,
CAM, probiotic/prebiotic and surgical interventions, which results in
extra heterogeneity in our findings. Our results are arguably more
extensive, particularly in the reporting of safety‐related outcomes
and adverse events, and go beyond the descriptive in the analysis of
changes between time periods by including statistical testing.
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Furthermore, we focused on primary and secondary endpoints (with
supplementary analysis of other outcomes), whereas Ma et al consid-
ered all outcomes in a singular analysis. This results in differences in
the breadth and depth of scope of the reviews and some nuances in
key findings between the two studies. For example, Ma et al found
that a higher proportion of studies used CDAI, which likely reflects
the requirement that trials must have used CDAI (or the Harvey‐
Bradshaw Index) at enrolment to be included. Their focus on a more
restricted range of therapies may also explain the higher proportion
of studies reporting adverse events, as our results included trials of
less traditional therapies. Ma et al also found that CDAI 100 was
more prevalent as a measure of response than in our results
(although we found a statistically significant increase in use over
time), and reported an increased use of faecal calprotectin. These
results may reflect some more recent trials included in their review.
The use of CDAI as a requirement for trial inclusion in their system-
atic review reduces the ability of the Ma et al review to assess
changes in the use of CDAI. We have been able to include such
analysis in our paper, and confirm a statistically significant increase
in CDAI100, whereas the use of CDAI overall has remained relatively
consistent.
Our study has limitations. Whilst it includes a comprehensive
listing of outcomes from available Crohn's disease trials, we cannot
account for publication bias. The results would have been strength-
ened by the consideration of nonrandomised controlled trials and
observational studies. In particular, this would help to characterise
important longer term harms. We did not assess the validity or
reliability of the outcome measures identified in the review,
although this would form a part of any core outcome set develop-
ment process.
Our study confirms the variability that exists in reporting of out-
comes in published clinical trials of interventions for Crohn's disease.
These data provide a comprehensive resource to support current
efforts7 to redefine optimal outcomes and measurement tools to be
included in future studies of comparative effectiveness.
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